The significance of cytological mesothelial atypia diagnosed from peritoneal washings performed during risk-reducing salpingo-oophorectomy

Gynecologic Oncology

Volumn 102, Issue 2, 2006, Pages 315-318

  Eitan, Ram ^a,b   Soslow, Robert ^b   Lin, Oscar ^b   Kauff, Noah D ^b   Liu, Lisa ^b   Barakat, Richard R ^b   Chi, Dennis S ^b  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

BRCA1; BRCA2; Breast cancer; Mesothelial atypia; Ovarian cancer; Peritoneal washings; Risk reducing salpingo oophorectomy

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ABDOMINAL SURGERY; ADULT; AGED; ARTICLE; BREAST CANCER; COHORT ANALYSIS; CONTROLLED STUDY; CYTOLOGY; DEMOGRAPHY; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC PROCEDURES; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; MESOTHELIUM; OUTCOME ASSESSMENT; PERITONEUM; PERITONEUM CANCER; PRIORITY JOURNAL; RISK REDUCTION; SALPINGOOOPHORECTOMY; STATISTICAL SIGNIFICANCE; SURGICAL TECHNIQUE;

ADULT; AGED; EPITHELIUM; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; OVARIECTOMY; PERITONEAL CAVITY; PERITONEAL NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 33745876302     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.12.021     Document Type: Article

References (17)

1. King M.C., Marks J.H., Mandell J.B., and New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302 5645 (2003) 643-646
2. Narod S.A. Modifiers of risk of hereditary breast and ovarian cancer. Nat. Rev., Cancer 2 2 (2002) 113-123
3. Levy-Lahad E., Catane R., Eisenberg S., et al. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am. J. Hum. Genet. 60 5 (1997) 1059-1067
4. Struewing J.P., Hartge P., Wacholder S., et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N. Engl. J. Med. 336 20 (1997) 1401-1408
5. Ford D., Easton D.F., Stratton M., et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 62 3 (1998) 676-689
6. Satagopan J.M., Boyd J., Kauff N.D., Robson M., Scheuer L., Narod S., et al. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin. Cancer Res. 8 12 (2002) 3776-3781
7. Kauff N.D., Satagopan J.M., Robson M.E., et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 346 21 (2002) 1609-1615 [electronic publication 2002 May 20]
8. Rebbeck T.R., Lynch H.T., Neuhausen S.L., et al., Prevention and Observation of Surgical End Points Study Group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 346 21 (2002) 1616-1622 [electronic publication 2002 May 20]
9. Rosen B., Kwon J., Fung Kee Fung M., Gagliardi A., Chambers A., and Cancer Care Ontario's Practice Guidelines Initiative Gynecology Cancer Disease Site Group. Systematic review of management options for women with a hereditary predisposition to ovarian cancer. Gynecol. Oncol. 93 2 (2004) 280-286 [Review]
10. Lu K.H., Garber J.E., Cramer D.W., et al. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J. Clin. Oncol. 18 14 (2000) 2728-2732
11. Powell C.B., Kenley E., Chen L.M., et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J. Clin. Oncol. 23 1 (2005) 127-132
12. Colgan T.J., Boerner S.L., Murphy J., Cole D.E., Narod S., and Rosen B. Peritoneal lavage cytology: an assessment of its value during prophylactic oophorectomy. Gynecol. Oncol. 85 3 (2002) 397-403
13. Scheuer L., Kauff N., Robson M., et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J. Clin. Oncol. 20 5 (2002) 1260-1268
14. SGO clinical practice committee statement on prophylactic salpingo-oophorectomy. Gynecol. Oncol. 98 (2005) 179-181
15. Karlan B.Y. Defining cancer risks for BRCA germline mutation carriers: implications for surgical prophylaxis. Gynecol. Oncol. 92 2 (2004) 519-520
16. Lavie O., Hornreich G., Ben-Arie A., et al. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma. Gynecol. Oncol. 92 2 (2004) 521-524
17. Levine D.A., Lin O., Barakat R.R., et al. Risk of endometrial carcinoma associated with BRCA mutation. Gynecol. Oncol. 80 3 (2001) 395-398